- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02754349
Validation Study of Pulse Wave Velocity and Augmentation Index in Atrial Fibrillation
September 6, 2016 updated by: Rogier Caluwe, Onze Lieve Vrouw Hospital
Assessment of Pulse Wave Velocity and Augmentation Index in Patients With Atrial Fibrillation Before and After Electrical Cardioversion: a Validation Study.
This study aims to evaluate the reliability of measurements of arterial stiffness (pulse wave velocity (PWV), pulse wave contour analysis (PWA), central augmentation index (AIx) and pulse pressure (PP)) in atrial fibrillation (AF).
For this purpose 30 AF patients scheduled for electrical cardioversion will be included.
PWV and PWA measurements will be carried out before and after cardioversion.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In recent years the role of arterial stiffness in the development of cardiovascular diseases has garnered attention.
Indeed, arterial stiffness is now well accepted as one of the most important determinants of increasing systolic and pulse pressure thus playing a germane role in the risk of stroke and myocardial infarction.
Longitudinal epidemiological studies have demonstrated the independent predictive value of arterial stiffness for cardiovascular events after adjustment for classical cardiovascular risk factors.
Arterial stiffness is now a recognized intermediate endpoint for cardiovascular events.
The pressure wave speed in large arteries is directly related to square root of the elastic modulus of the arterial wall (Moens-Korteweg Equation).
Carotid-femoral PWV is considered the gold standard method for assessing aortic stiffness.
The stiffness gradient along the aorta and central arteries, local arterial branchings and narrowing of the arterial lumen cause partial reflections of forward pressure waves traveling back to the central aorta.
Forward and reflected pressure waves overlap, and the final amplitude and shape of the pulse pressure wave are determined by the phase timing of these component waves.
In the aorta, forward and reflected waves are not in phase.
In subjects with low PWV, reflected waves reach the central arteries during late-systole and diastole, increasing the aortic pressure in early diastole, which is physiologically advantageous.
With increasing PWV, the reflected waves return earlier and impact on the central arteries during systole, thereby augmenting systolic and left ventricular pressure.
This is why increasing PWV is accompanied by increasing AIx (defined as the difference between the second and first systolic pressure peak) and central PP.
AIx and central PP depend on the speed of wave travel, the amplitude of reflected wave and the duration and pattern of ventricular ejection, especially with respect to change in heart rate and ventricular contractility.
Where PWV is considered a direct measure of arterial stiffness, central PP and AIx are only indirect, surrogate measures.
However, they provide additional information concerning wave reflections.
Whether PWV, AIx and central PP measurements are influenced by the presence of AF is unknown.
Studying AF patients before and after elective electrical cardioversion offers an appropriate setting to evaluate the effect of heart rate and rhytm on PWV, AIx and central PP.
Patient specific confounding factors are minimized because each patient serves as its own control.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aalst, Belgium, 9300
- OLV Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- man or woman, age ≥18 years
- signed written informed consent
- atrial fibrillation or flutter
- scheduled for elective electrical cardioversion
Exclusion Criteria:
- inability to understand the nature, scope and possible consequences of the study
- clinical conditions that could hamper hemodynamic measurements (absence of femoral pulse, systolic blood pressure < 90 mmHg)
- presence of prosthetic material (grafts, stents or stent-grafts) in the aorta or femoral arteries
- any condition precluding the execution of the cardioversion procedure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Validation
SphygmoCor version 7, AtCor Medical, Sydney, Australia
|
Pulse wave velocity, augmentation index and central blood pressure measurement with applanation tonometry before and after electrical cardioversion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pulse Wave Velocity (in meters per second) before and after cardioversion
Time Frame: immediate
|
with assessment of agreement on the individual level and systematic bias using the group average before and after cardioversion
|
immediate
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Augmentation Index (in percent) before and after cardioversion
Time Frame: immediate
|
with assessment of agreement on the individual level and systematic bias using the group average before and after cardioversion.hemodynamic
parameters obtained from pulse wave analysis (including AIx en central blood pressure)
|
immediate
|
|
Central systolic blood pressure, diastolic blood pressure, mean arterial pressure and pulse pressure (in mmHg) before and after cardioversion and their potential effects on changes in PWV and AI after cardioversion
Time Frame: immediate
|
immediate
|
|
|
Heart rate (beats/min) before and after cardioversion and their potential effects on changes in PWV and AI after cardioversion.
Time Frame: immediate
|
immediate
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Actual)
May 1, 2016
Study Completion (Actual)
May 1, 2016
Study Registration Dates
First Submitted
March 28, 2016
First Submitted That Met QC Criteria
April 25, 2016
First Posted (Estimate)
April 28, 2016
Study Record Updates
Last Update Posted (Estimate)
September 7, 2016
Last Update Submitted That Met QC Criteria
September 6, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014/091
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Medtronic Cardiac Ablation SolutionsRecruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation | Atrial Fibrillation (AF)Australia, United States, France, Belgium, Switzerland, Czechia
-
China National Center for Cardiovascular DiseasesRecruitingAtrial Fibrillation Ablation | Atrial Fibrillation (AF) | Radiofrequency Catheter Ablation | Atrial Fibrillation Recurrent | Pulsed Field AblationChina
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Boston Scientific CorporationRecruitingAtrial Fibrillation (AF) | Persistant Atrial FibrillationUnited States, Spain, Belgium, France, Netherlands, Germany, Hong Kong
-
CortexAblacon, Inc.Active, not recruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Boston Scientific CorporationRecruitingParoxysmal Atrial Fibrillation | Persistent Atrial FibrillationHong Kong, Czechia, Croatia, Taiwan
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Medtronic Cardiac Ablation SolutionsNot yet recruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation
-
University Medical Centre LjubljanaEnrolling by invitationPersistent Atrial Fibrillation | Persistent Atrial Fibrillation LongstandingSlovenia
Clinical Trials on SphygmoCor version 7, AtCor Medical, Sydney, Australia
-
University Hospitals Coventry and Warwickshire...CompletedArterial StiffnessUnited Kingdom